Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial.
Leukemia
View this publicationLeukemia
View this publicationCancer discovery
View this publicationBMC cancer
View this publicationTherapeutic advances in musculoskeletal disease
View this publicationBMC medical imaging
View this publicationMolecular cancer
View this publicationBMC biology
View this publicationLupus
View this publicationJournal of cancer research and clinical oncology
View this publicationMolecular cancer
View this publication